A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

D Dylan C. Gagler (1Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY) H Hussein Ghamlouch (4Hématopoïèse et Immunologie, Unité de Recherche 4666, Université de Picardie Jules Verne, Amiens, France) D Di Zhang P Patrick Blaney (1Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY) A Avital Tenenbaum (1NYU Langone Health, Multiple Myeloma Research Program, New York, United States) J James Langton (1NYU Langone Health, Multiple Myeloma Research Program, New York, United States) M Marine Armand (2Gustave Roussy, la Recherche Médicale, Villejuif, France) A Alexandre Eeckhoutte (2Gustave Roussy, la Recherche Médicale, Villejuif, France) A Amina Joudat (2Gustave Roussy, la Recherche Médicale, Villejuif, France) M Michael Degaud (1Gustave Roussy, Villejuif, France) M Michela Esposito (Department of Medical Physics and Biomedical Engineering) G Gaurav Varma (4NYU Langone Health, New York, United States) Y Yubao Wang (Department of Cancer Biology, Dana-Farber Cancer Institute) S Sanghoon Lee S Sanxiong Liu (HHMI, New York University Langone Health) O Oscar Lahoud (11. Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, United States) D David Kaminetzky (11. Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, United States) M Marc Braunstein (11. Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, United States) L Louis Williams F Florence Nguyen-Khac (31APHP, Paris, France) B Brian Walker (1Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, United States) D Damien Roos-Weil (5Drug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Université Paris Cité, INSERM UMRS 1138, Sorbonne Université, Paris, France) F Faith E. Davies (1Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY) O Olivier A. Bernard (4Université Paris-Saclay, INSERM, Gustave Roussy, Dynamique Moléculaire de la Transformation Hématopoïétique, Villejuif, France) G Gareth J. Morgan

Abstract

Abstract We carried out a single-cell multiomic analysis on a series of MYD88-mutated Waldenström macroglobulinemia (WM) patients and identified 2 distinct subtypes of disease, memory B-cell (MBC)–like and plasma cell (PC)–like, based on their expression of key lineage defining genes. Biologically, the subtypes are characterized by their variable capacity to differentiate fully toward a PC and exhibit unique transcriptomic, chromatin accessibility, and genomic profiles. The MBC-like subtype is unable to differentiate beyond the MBC stage, upregulates key MBC genes, and is characterized by upregulated B-cell receptor and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling. In contrast, the PC-like subtype can partially differentiate toward a PC, upregulates key PC genes, has enhanced NF-κB signaling, and has an upregulated unfolded protein response. Pseudotime trajectory analysis of combined single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin with sequencing supports the variable differentiation capacity of each subtype and implicate key transcription factors SPI1, SPIB, BCL11A, and XBP1 in these features. The existence and generalizability of the 2 disease subtypes were validated further using hierarchical clustering of bulk RNA-sequencing data from a secondary set of patients. The biological significance of the subtypes was further established using whole-genome sequencing, in which it was shown that CXCR4, NIK, and ARID1A mutations occur predominantly in the MBC-like subtype, and 6q deletions in the PC-like subtype. We conclude that the variable differentiation blockade seen in WM manifests itself clinically as 2 disease subtypes with distinct epigenetic, mutational, transcriptional, and clinical features, with potential implications for WM treatment strategies.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 10
Published September 04, 2025
Pages 1225-1238
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (25)

D

Dylan C. Gagler

1Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY

H

Hussein Ghamlouch

4Hématopoïèse et Immunologie, Unité de Recherche 4666, Université de Picardie Jules Verne, Amiens, France

D

Di Zhang

P

Patrick Blaney

1Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY

A

Avital Tenenbaum

1NYU Langone Health, Multiple Myeloma Research Program, New York, United States

J

James Langton

1NYU Langone Health, Multiple Myeloma Research Program, New York, United States

M

Marine Armand

2Gustave Roussy, la Recherche Médicale, Villejuif, France

A

Alexandre Eeckhoutte

2Gustave Roussy, la Recherche Médicale, Villejuif, France

A

Amina Joudat

2Gustave Roussy, la Recherche Médicale, Villejuif, France

M

Michael Degaud

1Gustave Roussy, Villejuif, France

M

Michela Esposito

Department of Medical Physics and Biomedical Engineering

G

Gaurav Varma

4NYU Langone Health, New York, United States

Y

Yubao Wang

Department of Cancer Biology, Dana-Farber Cancer Institute

S

Sanghoon Lee

S

Sanxiong Liu

HHMI, New York University Langone Health

O

Oscar Lahoud

11. Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, United States

D

David Kaminetzky

11. Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, United States

M

Marc Braunstein

11. Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, United States

L

Louis Williams

F

Florence Nguyen-Khac

31APHP, Paris, France

B

Brian Walker

1Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, United States

D

Damien Roos-Weil

5Drug Resistance in Hematological Malignancies Team, Centre de Recherche des Cordeliers, Université Paris Cité, INSERM UMRS 1138, Sorbonne Université, Paris, France

F

Faith E. Davies

1Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY

O

Olivier A. Bernard

4Université Paris-Saclay, INSERM, Gustave Roussy, Dynamique Moléculaire de la Transformation Hématopoïétique, Villejuif, France

G

Gareth J. Morgan